<DOC>
	<DOCNO>NCT01448018</DOCNO>
	<brief_summary>The purpose study compare ranibizumab injection hemodilution early phase Central Retinal Vein Occlusion ( CRVO ) determine combination treatment may synergic effect .</brief_summary>
	<brief_title>Hemodilution Versus Ranibizumab Early-onset Central Retinal Vein Occlusion</brief_title>
	<detailed_description>Patients recent-onset CRVO ( last less 1 month ) randomly assign one 3 group : hemodilution use erythrocytapheresis alone , 3 monthly injection ranibizumab alone , . Patients follow monthly 6-month study .</detailed_description>
	<mesh_term>Retinal Vein Occlusion</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>CRVO confirm fluorescein angiography duration onset 1 month less visual acuity 20/32 less neovascular complication extensive retinal ischemia require prompt panretinal photocoagulation hematocrit level lower 38 % previous laser surgery study eye , etc</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>